Home > Journals > The Quarterly Journal of Nuclear Medicine and Molecular Imaging > Past Issues > Articles online first > The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2019 Jul 01

CURRENT ISSUE
 

JOURNAL TOOLS

eTOC
To subscribe
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Publication history
Reprints
Permissions
Cite this article as

 

 

The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2019 Jul 01

DOI: 10.23736/S1824-4785.19.03157-1

Copyright © 2019 EDIZIONI MINERVA MEDICA

language: English

[18F]fluorodeoxyglucose-positron emission tomography and glucose-transporter type 1 (GLUT-1) expression in untreated primary small bowel adenocarcinoma

Thomas HAUSER 1, 2, Tina SCHALLER 3, Xiang LI 4, Thomas WIDMANN 5, Michael C. KREISSL 1, 6

1 Department of Nuclear Medicine, Central Hospital Augsburg, Augsburg, Germany; 2 Radiologie Augsburg-Friedberg, Augsburg, Germany; 3 Department of Pathology, Central Hospital Augsburg, Augsburg, Germany; 4 Division of Nuclear Medicine, Department of Biomedical Imaging and Image-Guided Therapy, Vienna General Hospital, Medical University of Vienna, Vienna, Austria; 5 Department of Oncology, Asklepiosklinik Triberg, Triberg, Germany; 6 Department of Radiology and Nuclear Medicine, University Hospital Magdeburg, Magdeburg, Germany


PDF


BACKGROUND: Literature reporting [18F]fluorodexoyglucose positron emission tomography (FDG-PET) of small bowel adenocarcinoma, a rare tumor, is sparse. To assess FDG uptake in small bowel adenocarcinoma, we retrospectively analyzed a large, single-center database and determined the expression of glucose-transporter type 1 (GLUT-1).
METHODS: Screening of PET datasets in the database (N = 28,961 scans) for untreated histologically- confirmed primary small bowel adenocarcinoma revealed evaluable PET datasets for eight patients. Maximum and peak standardized uptake values (SUVmax and SUVpeak, respectively) were calculated via volume-of-interest (VOI) analysis. Additionally, GLUT-1 expression on tumor specimens was prospectively immunohistochemically assessed.
RESULTS: All primary tumors showed high FDG uptake: mean SUVmax was 9.5 ± 2.6 (range: 5.0-13.0) and SUVpeak, 8.1 ± 2.3 (range: 3.9-10.7). Corresponding biopsy specimens (n = 7) demonstrated high GLUT-1 expression.
CONCLUSIONS: Primary small bowel adenocarcinomas have a high GLUT-1 expression. Tumor lesions consistently demonstrated high FDG uptake pre-treatment, suggesting FDG-PET utility in staging and follow-up of these tumors.


KEY WORDS: Small bowel; Adenocarcinoma; FDG-PET; FDG uptake; GLUT-1

top of page